

Special Issue

Recent Advances in Antitubercular Drug Discovery

Message from the Guest Editor

Tuberculosis (TB) is still the leading cause of death from a single infectious disease agent, with an estimated 1.7 billion people infected with *Mycobacterium tuberculosis*, and more than 10 million new cases each year. The current anti-TB therapy has reduced the mortality, but it requires a long treatment period, and can have serious adverse reactions. Moreover, multidrug-resistant (MDR) and extensively drug-resistant (XDR) *M. tuberculosis* strains have now spread worldwide and become a global issue. For these reasons novel TB drugs and novel drug targets are needed; indeed, considerable efforts, involving different approaches and expertise, have been made in the last years. The aim of this Special Issue is, therefore, to collect research papers, short communications, and critical review articles, that are focused on the discovery and development of novel antitubercular drugs, new potential biological targets, and therapeutic approaches.

Guest Editor

Dr. Chiarelli Laurent

Department of Biology and Biotechnology "Lazzaro Spallanzani",
University of Pavia, 27100 Pavia, Italy

Deadline for manuscript submissions

closed (31 December 2019)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/27753

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).